These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 16216315

  • 1. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.
    Long HJ, Monk BJ, Huang HQ, Grendys EC, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group.
    Gynecol Oncol; 2006 Mar; 100(3):537-43. PubMed ID: 16216315
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    Long HJ, Bundy BN, Grendys EC, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV, Gynecologic Oncology Group Study.
    J Clin Oncol; 2005 Jul 20; 23(21):4626-33. PubMed ID: 15911865
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
    Long HJ, Nelimark RA, Podratz KC, Suman V, Keeney GL, Nikcevich DA, Kugler JW, Rowland KM, Kardinal CG, Wos EJ.
    Gynecol Oncol; 2006 Mar 20; 100(3):501-5. PubMed ID: 16185755
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH, Mailliard JA, Suman VJ, Edmonson JH, Creagan ET, Nair S, Levitt R, Kugler JW.
    Cancer; 2002 Apr 15; 94(8):2224-31. PubMed ID: 12001121
    [Abstract] [Full Text] [Related]

  • 6. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study.
    McQuellon RP, Thaler HT, Cella D, Moore DH.
    Gynecol Oncol; 2006 May 15; 101(2):296-304. PubMed ID: 16376417
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina.
    Long HJ, Cross WG, Wieand HS, Webb MJ, Mailliard JA, Kugler JW, Tschetter LK, Kardinal CG, Ebbert LP, Rayson S.
    Gynecol Oncol; 1995 May 15; 57(2):235-9. PubMed ID: 7729741
    [Abstract] [Full Text] [Related]

  • 8. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
    Inoue T, Obara T, Saito M, Kumazawa T, Yuasa T, Matuura S, Tsuchiya N, Satoh S, Habuchi T.
    Hinyokika Kiyo; 2007 Sep 15; 53(9):613-8. PubMed ID: 17933135
    [Abstract] [Full Text] [Related]

  • 9. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.
    Long HJ, Langdon RM, Cha SS, Veeder MH, Pfeifle DM, Krook JE, Ebbert LP, Tschetter LK, Roshon SG.
    Gynecol Oncol; 1995 Aug 15; 58(2):240-3. PubMed ID: 7622111
    [Abstract] [Full Text] [Related]

  • 10. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 11. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
    Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ.
    Gynecol Oncol; 2009 Jan 15; 112(1):85-9. PubMed ID: 18977518
    [Abstract] [Full Text] [Related]

  • 12. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
    Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, Liao S.
    J Clin Oncol; 2004 Oct 01; 22(19):3902-8. PubMed ID: 15459211
    [Abstract] [Full Text] [Related]

  • 13. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P, Gravis G, Bladou F, Lechevallier E, Baume D, Camerlo J, Cowen D, Coulange C, Serment G, Resbeut M, Maraninchi D.
    Eur Cytokine Netw; 1996 Sep 01; 7(3):395-9. PubMed ID: 8954183
    [Abstract] [Full Text] [Related]

  • 14. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, De Braud FG, Gianni AM, Salvioni R.
    Clin Genitourin Cancer; 2014 Jun 01; 12(3):203-209.e1. PubMed ID: 24394493
    [Abstract] [Full Text] [Related]

  • 15. [Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].
    Ochi T, Ozawa A, Tanji N, Yanagihara Y, Yanagaki T, Miyauchi Y, Ikeda T, Shimamoto K, Toshino A, Sugawara T, Hamada H, Yokoyama M.
    Nihon Hinyokika Gakkai Zasshi; 2006 Sep 01; 97(6):777-81. PubMed ID: 17025209
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E, AGO-OVAR, GINECO.
    J Natl Cancer Inst; 2006 Aug 02; 98(15):1036-45. PubMed ID: 16882940
    [Abstract] [Full Text] [Related]

  • 17. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
    Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS.
    Anticancer Res; 2001 Aug 02; 21(1B):711-5. PubMed ID: 11299831
    [Abstract] [Full Text] [Related]

  • 18. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature.
    Long HJ, Rayson S, Podratz KC, Abu-Ghazaleh S, Suman V, Hartmann LC, Levitt R, Nair S, Hatfield AK, Knost JA.
    Am J Clin Oncol; 2002 Dec 02; 25(6):547-51. PubMed ID: 12477995
    [Abstract] [Full Text] [Related]

  • 19. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    J Clin Oncol; 2006 Feb 01; 24(4):579-86. PubMed ID: 16446330
    [Abstract] [Full Text] [Related]

  • 20. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H.
    Hinyokika Kiyo; 2004 Oct 01; 50(10):667-71. PubMed ID: 15575216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.